Abstract
Dopamine function and reward processing are highly interrelated and involve common brain regions afferent to the nucleus accumbens, within the mesolimbic pathway. Although dopamine function and reward system neural activity are impaired in most psychiatric disorders, it is unknown whether alterations in the dopamine system underlie variations in reward processing across a continuum encompassing health and these disorders. We explored the relationship between dopamine function and neural activity during reward anticipation in 27 participants including healthy volunteers and psychiatric patients with schizophrenia, depression, or cocaine addiction, using functional magnetic resonance imaging (fMRI) and positron emission tomography (PET) multimodal imaging with a voxel-based statistical approach. Dopamine transporter (DAT) availability was assessed with PET and [11C]PE2I as a marker of presynaptic dopamine function, and reward-related neural response was assessed using fMRI with a modified Monetary Incentive Delay task. Across all the participants, DAT availability in the midbrain correlated positively with the neural response to anticipation of reward in the nucleus accumbens. Moreover, this relationship was conserved in each clinical subgroup, despite the heterogeneity of mental illnesses examined. For the first time, a direct link between DAT availability and reward anticipation was detected within the mesolimbic pathway in healthy and psychiatric participants, and suggests that dopaminergic dysfunction is a common mechanism underlying the alterations of reward processing observed in patients across diagnostic categories. The findings support the use of a dimensional approach in psychiatry, as promoted by the Research Domain Criteria project to identify neurobiological signatures of core dysfunctions underling mental illnesses.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Arakawa R, Ichimiya T, Ito H, Takano A, Okumura M, Takahashi H et al (2009). Increase in thalamic binding of [(11)C]PE2I in patients with schizophrenia: a positron emission tomography study of dopamine transporter. J Psychiatr Res 43: 1219–1223.
Artiges E, Leroy C, Dubol M, Prat M, Pepin A, Mabondo A et al (2017). Striatal and extrastriatal dopamine transporter availability in schizophrenia and its clinical correlates: a voxel-based and high-resolution PET study. Schizophr Bull (e-pub ahead of print).
Buckholtz JW, Treadway MT, Cowan RL, Woodward ND, Benning SD, Li R et al (2010). Mesolimbic dopamine reward system hypersensitivity in individuals with psychopathic traits. Nat Neurosci 13: 419–421.
Camara E, Kramer UM, Cunillera T, Marco-Pallares J, Cucurell D, Nager W et al (2010). The effects of COMT (Val108/158Met) and DRD4 (SNP-521) dopamine genotypes on brain activations related to valence and magnitude of rewards. Cereb Cortex 20: 1985–1996.
Carelli RM, Wightman RM (2004). Functional microcircuitry in the accumbens underlying drug addiction: insights from real-time signaling during behavior. Curr Opin Neurobiol 14: 763–768.
Chau DT, Roth RM, Green AI (2004). The neural circuitry of reward and its relevance to psychiatric disorders. Curr Psychiatry Rep 6: 391–399.
Chen F, Lawrence AJ (2003). The effects of antidepressant treatment on serotonergic and dopaminergic systems in Fawn-Hooded rats: a quantitative autoradiography study. Brain Res 976: 22–29.
Davis KL, Kahn RS, Ko G, Davidson M (1991). Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148: 1474–1486.
Delgado PL (2006). Serotonin noradrenaline reuptake inhibitors: new hope for the treatment of chronic pain. Int J Psychiatry Clin Pract 10 (Suppl 2): 16–21.
Dreher JC, Kohn P, Kolachana B, Weinberger DR, Berman KF (2009). Variation in dopamine genes influences responsivity of the human reward system. Proc Natl Acad Sci USA 106: 617–622.
Dreher JC, Meyer-Lindenberg A, Kohn P, Berman KF (2008). Age-related changes in midbrain dopaminergic regulation of the human reward system. Proc Natl Acad Sci USA 105: 15106–15111.
Fusar-Poli P, Meyer-Lindenberg A (2013). Striatal presynaptic dopamine in schizophrenia, part II: meta-analysis of [(18)F/(11)C]-DOPA PET studies. Schizophr Bull 39: 33–42.
Graf H, Metzger CD, Walter M, Abler B (2016). Serotonergic antidepressants decrease hedonic signals but leave learning signals in the nucleus accumbens unaffected. Neuroreport 27: 18–22.
Greer SM, Goldstein AN, Knutson B, Walker MP (2016). A genetic polymorphism of the human dopamine transporter determines the impact of sleep deprivation on brain responses to rewards and punishments. J Cogn Neurosci 28: 803–810.
Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ (1997). Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 6: 279–287.
Haber SN, Behrens TE (2014). The neural network underlying incentive-based learning: implications for interpreting circuit disruptions in psychiatric disorders. Neuron 83: 1019–1039.
Hagele C, Schlagenhauf F, Rapp M, Sterzer P, Beck A, Bermpohl F et al (2015). Dimensional psychiatry: reward dysfunction and depressive mood across psychiatric disorders. Psychopharmacology 232: 331–341.
Halldin C, Erixon-Lindroth N, Pauli S, Chou YH, Okubo Y, Karlsson P et al (2003). [(11)C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain. Eur J Nucl Med Mol Imaging 30: 1220–1230.
Hirth N, Meinhardt MW, Noori HR, Salgado H, Torres-Ramirez O, Uhrig S et al (2016). Convergent evidence from alcohol-dependent humans and rats for a hyperdopaminergic state in protracted abstinence. Proc Natl Acad Sci USA 113: 3024–3029.
Hommer DW, Bjork JM, Gilman JM (2011). Imaging brain response to reward in addictive disorders. Ann N Y Acad Sci 1216: 50–61.
Ikemoto S (2007). Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens–olfactory tubercle complex. Brain Res Rev 56: 27–78.
Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K et al (2010). Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry 167: 748–751.
Juckel G, Schlagenhauf F, Koslowski M, Filonov D, Wustenberg T, Villringer A et al (2006). Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics. Psychopharmacology (Berl) 187: 222–228.
Kapur S (2003). Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 160: 13–23.
Karila L, Leroy C, Dubol M, Trichard C, Mabondo A, Marill C et al (2016). Dopamine transporter correlates and occupancy by modafinil in cocaine-dependent patients: a controlled study with high-resolution PET and [11C]-PE2I. Neuropsychopharmacology 41(9): 2294–2302.
Kim C-E, Lee M-H, Lee P-G, Choe W-S, Pyo S-J (2004). Correlation between psychopathology and dopamine transporter density in striatum before and after taking olanzapine assessed with IPT-SPECT in first episode schizophrenia. Korean J Psychopharmacol 15: 8.
Knutson B, Adams CM, Fong GW, Hommer D (2001a). Anticipation of increasing monetary reward selectively recruits nucleus accumbens. J Neurosci 21: RC159.
Knutson B, Fong GW, Adams CM, Varner JL, Hommer D (2001b). Dissociation of reward anticipation and outcome with event-related fMRI. Neuroreport 12: 3683–3687.
Knutson B, Westdorp A, Kaiser E, Hommer D (2000). FMRI visualization of brain activity during a monetary incentive delay task. Neuroimage 12: 20–27.
Kugaya A, Seneca NM, Snyder PJ, Williams SA, Malison RT, Baldwin RM et al (2003). Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology 28: 413–420.
Lammertsma AA, Hume SP (1996). Simplified reference tissue model for PET receptor studies. Neuroimage 4 (3 Pt 1): 153–158.
Lavalaye J, Knol RJ, de Bruin K, Reneman L, Janssen AG, Booij J (2000). [123I]FP-CIT binding in rat brain after acute and sub-chronic administration of dopaminergic medication. Eur J Nucl Med 27: 346–349.
Leroy C, Karila L, Martinot JL, Lukasiewicz M, Duchesnay E, Comtat C et al (2012). Striatal and extrastriatal dopamine transporter in cannabis and tobacco addiction: a high-resolution PET study. Addict Biol 17: 981–990.
Macoveanu J, Fisher PM, Haahr ME, Frokjaer VG, Knudsen GM, Siebner HR (2014). Effects of selective serotonin reuptake inhibition on neural activity related to risky decisions and monetary rewards in healthy males. Neuroimage 99: 434–442.
Malison RT, Best SE, Wallace EA, McCance E, Laruelle M, Zoghbi SS et al (1995). Euphorigenic doses of cocaine reduce [123I]beta-CIT SPECT measures of dopamine transporter availability in human cocaine addicts. Psychopharmacology 122: 358–362.
McHugh PC, Buckley DA (2015). The structure and function of the dopamine transporter and its role in CNS diseases. Vitam Horm 98: 339–369.
Naranjo CA, Tremblay LK, Busto UE (2001). The role of the brain reward system in depression. Prog Neuropsychopharmacol Biol Psychiatry 25: 781–823.
Narendran R, Martinez D (2008). Cocaine abuse and sensitization of striatal dopamine transmission: a critical review of the preclinical and clinical imaging literature. Synapse 62: 851–869.
Nees F, Vollstadt-Klein S, Fauth-Buhler M, Steiner S, Mann K, Poustka L et al (2012). A target sample of adolescents and reward processing: same neural and behavioral correlates engaged in common paradigms? Exp Brain Res 223: 429–439.
Nielsen MO, Rostrup E, Wulff S, Bak N, Broberg BV, Lublin H et al (2012). Improvement of brain reward abnormalities by antipsychotic monotherapy in schizophrenia. Arch Gen Psychiatry 69: 1195–1204.
Pinsonneault JK, Han DD, Burdick KE, Kataki M, Bertolino A, Malhotra AK et al (2011). Dopamine transporter gene variant affecting expression in human brain is associated with bipolar disorder. Neuropsychopharmacology 36: 1644–1655.
Reith ME, Xu C, Zhang L, Coffey LL (1996). Translocation of dopamine and binding of WIN 35,428 measured under identical conditions in cells expressing the cloned human dopamine transporter. Naunyn Schmiedebergs Arch Pharmacol 354: 295–304.
Rominger A, Cumming P, Brendel M, Xiong G, Zach C, Karch S et al (2015). Altered serotonin and dopamine transporter availabilities in brain of depressed patients upon treatment with escitalopram: a [123 I]beta-CIT SPECT study. Eur Neuropsychopharmacol 25: 873–881.
Schott BH, Minuzzi L, Krebs RM, Elmenhorst D, Lang M, Winz OH et al (2008). Mesolimbic functional magnetic resonance imaging activations during reward anticipation correlate with reward-related ventral striatal dopamine release. J Neurosci 28: 14311–14319.
Schultz W (1997). Dopamine neurons and their role in reward mechanisms. Curr Opin Neurobiol 7: 191–197.
Seki C, Ito H, Ichimiya T, Arakawa R, Ikoma Y, Shidahara M et al (2010). Quantitative analysis of dopamine transporters in human brain using [11C]PE2I and positron emission tomography: evaluation of reference tissue models. Ann Nucl Med 24: 249–260.
Sjoholm H, Bratlid T, Sundsfjord J (2004). 123I-beta-CIT SPECT demonstrates increased presynaptic dopamine transporter binding sites in basal ganglia in vivo in schizophrenia. Psychopharmacology 173: 27–31.
Stoy M, Schlagenhauf F, Sterzer P, Bermpohl F, Hagele C, Suchotzki K et al (2012). Hyporeactivity of ventral striatum towards incentive stimuli in unmedicated depressed patients normalizes after treatment with escitalopram. J Psychopharmacol 26: 677–688.
Volkow ND, Fowler JS, Wang GJ (2004). The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies. Neuropharmacology 47 (Suppl 1): 3–13.
Volkow ND, Wang GJ, Fischman MW, Foltin RW, Fowler JS, Abumrad NN et al (1997). Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 386: 827–830.
Volkow ND, Wang GJ, Fowler JS, Tomasi D, Telang F (2011). Addiction: beyond dopamine reward circuitry. Proc Natl Acad Sci USA 108: 15037–15042.
Walter H, Kammerer H, Frasch K, Spitzer M, Abler B (2009). Altered reward functions in patients on atypical antipsychotic medication in line with the revised dopamine hypothesis of schizophrenia. Psychopharmacology 206: 121–132.
Weiland BJ, Heitzeg MM, Zald D, Cummiford C, Love T, Zucker RA et al (2014). Relationship between impulsivity, prefrontal anticipatory activation, and striatal dopamine release during rewarded task performance. Psychiatry Res 223: 244–252.
Weiland BJ, Zucker RA, Zubieta JK, Heitzeg MM (2016). Striatal dopaminergic reward response relates to age of first drunkenness and feedback response in at-risk youth. Addict Biol 22: 502–512.
Whitton AE, Treadway MT, Pizzagalli DA (2015). Reward processing dysfunction in major depression, bipolar disorder and schizophrenia. Curr Opin Psychiatry 28: 7–12.
Zhou Z, Zhen J, Karpowich NK, Law CJ, Reith ME, Wang DN (2009). Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures. Nat Struct Mol Biol 16: 652–657.
Acknowledgements
We would like to thank Christine Baron, Vincent Brulon, Stéphane LeHelleix, Stéphane Demphel, Claude Comtat, Frédéric Dollé, Philippe Gervais, and Renaud Maroy from the Service Hospitalier Frédéric Joliot for their efficient technical support and 11C radioligand preparation. They thank Marie Prat, Audrey Pepin, and Audrey Mabondo for their help in PET processing and Pr. Maria-Joao Santiago-Ribeiro and Dr Renaud de Beaurepaire for their involvement in the recruitment of participants.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Neuropsychopharmacology website
Rights and permissions
About this article
Cite this article
Dubol, M., Trichard, C., Leroy, C. et al. Dopamine Transporter and Reward Anticipation in a Dimensional Perspective: A Multimodal Brain Imaging Study. Neuropsychopharmacol. 43, 820–827 (2018). https://doi.org/10.1038/npp.2017.183
Received:
Revised:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/npp.2017.183
This article is cited by
-
Striatal dopamine D2/D3 receptor regulation of human reward processing and behaviour
Nature Communications (2025)
-
Relief of neuropathic pain by cell-specific manipulation of nucleus accumbens dopamine D1- and D2-receptor-expressing neurons
Molecular Brain (2022)
-
Neural substrates of reward anticipation and outcome in schizophrenia: a meta-analysis of fMRI findings in the monetary incentive delay task
Translational Psychiatry (2022)
-
Dysregulation of iron homeostasis and methamphetamine reward behaviors in Clk1-deficient mice
Acta Pharmacologica Sinica (2022)
-
The reward for placebos: mechanisms underpinning placebo-induced effects on motor performance
European Journal of Applied Physiology (2022)
